

**REFERENCES:**

1. Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. *Breast Cancer Research*. 2020 Nov 4;22(1):121.
2. Toppmeyer DL, Press MF. Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer. *Cancer Med*. 2020 Jul 22;9(18):6463–72.
3. Frontiers | PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer | Oncology [Internet]. [cited 2022 May 12]. Available from: <https://www.frontiersin.org/articles/10.3389/fonc.2021.644737/full>
4. Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. *ESMO Open*. 2022 Apr 1;7(2):100409.
5. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell*. 2005 Jun 1;7(6):561–73.